Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial

BACKGROUND: Immunogenicity and safety of the AZD1222 (ChAdOx1 nCoV-19) vaccine was evaluated in Japanese adults in an ongoing phase 1/2, randomized, double-blind, parallel-group, placebo-controlled, multi-centre trial (NCT04568031). METHODS: Adults (n=256, age ≥18 years) seronegative for severe acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Asano, Michiko, Okada, Hiroshi, Itoh, Yohji, Hirata, Hajime, Ishikawa, Kensuke, Yoshida, Erika, Matsui, Akiko, Kelly, Elizabeth J., Shoemaker, Kathryn, Olsson, Urban, Vekemans, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531242/
https://www.ncbi.nlm.nih.gov/pubmed/34688944
http://dx.doi.org/10.1016/j.ijid.2021.10.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531242/
https://www.ncbi.nlm.nih.gov/pubmed/34688944
http://dx.doi.org/10.1016/j.ijid.2021.10.030

Ejemplares similares